Moderna, Inc. — Director's Dealing 2022

Oct 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-10-05

Reporting Person: Mock James M (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-05	Stock Option (Right to Buy)	$125.62	A	43876	Acquired	2032-10-05	Common Stock (43876)	Direct
2022-10-05	Restricted Stock Units	$0	A	23242	Acquired		Common Stock (23242)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.